MedBright AI Announces the Appointment of Christopher Heath as CEO and Termination of Letter of Intent
MedBright AI Investments Inc. (CSE:MBAI, OTCQB:MBAIF, FSE:Y30) has appointed Christopher Heath as its new Chief Executive Officer, effective August 9, 2024. Heath brings valuable experience from his previous role as CEO of Convalo Health Corp., a network of drug and alcohol treatment clinics. His expertise in the medical and technology sectors, combined with over a decade of experience in public capital markets, aligns with MedBright's mission of investing in AI-enabled healthcare solutions.
The company has also announced the termination of its previously announced letter of intent regarding a proposed acquisition by Numinus Wellness Inc. This strategic shift suggests MedBright AI is focusing on internal growth and development under new leadership.
MedBright AI Investments Inc. (CSE:MBAI, OTCQB:MBAIF, FSE:Y30) ha nominato Christopher Heath come nuovo Amministratore Delegato, con effetto dal 9 agosto 2024. Heath porta con sé un'esperienza preziosa dalla sua precedente posizione di CEO di Convalo Health Corp., una rete di cliniche per il trattamento di dipendenze da droghe e alcol. La sua competenza nei settori medico e tecnologico, unita a oltre un decennio di esperienza nei mercati di capitali pubblici, si allinea con la missione di MedBright di investire in soluzioni sanitarie abilitate all'IA.
La società ha inoltre annunciato la risoluzione della lettera di intenti precedentemente annunciata riguardante una proposta di acquisizione da parte di Numinus Wellness Inc. Questo cambiamento strategico suggerisce che MedBright AI si sta concentrando sulla crescita e sviluppo interni sotto una nuova leadership.
MedBright AI Investments Inc. (CSE:MBAI, OTCQB:MBAIF, FSE:Y30) ha nombrado a Christopher Heath como su nuevo Director Ejecutivo, con efecto a partir del 9 de agosto de 2024. Heath trae una valiosa experiencia de su anterior rol como CEO de Convalo Health Corp., una red de clínicas de tratamiento de drogas y alcohol. Su experiencia en los sectores médico y tecnológico, combinada con más de una década de experiencia en mercados de capitales públicos, se alinea con la misión de MedBright de invertir en soluciones de atención médica habilitadas por IA.
La empresa también ha anunciado la terminación de la carta de intenciones previamente anunciada respecto a una propuesta de adquisición por parte de Numinus Wellness Inc. Este cambio estratégico sugiere que MedBright AI se está enfocando en el crecimiento y desarrollo interno bajo un nuevo liderazgo.
MedBright AI Investments Inc. (CSE:MBAI, OTCQB:MBAIF, FSE:Y30)은 Christopher Heath를 새로운 최고 경영자로 임명하며, 2024년 8월 9일부터 효력이 발생합니다. Heath는 약물 및 알코올 치료 클리닉 네트워크인 Convalo Health Corp.의 CEO로서의 경험을 바탕으로 귀중한 경력을 가져옵니다. 의료 및 기술 분야의 전문성과 10년 이상의 공공 자본 시장 경험이 결합되어 MedBright의 AI 기반 의료 솔루션에 대한 투자 미션에 부합합니다.
회사는 또한 Numinus Wellness Inc.의 제안된 인수와 관련하여 이전에 발표된 의향서의 해지를 발표했습니다. 이 전략적 변화는 MedBright AI가 새로운 리더십 아래 내부 성장과 개발에 집중하고 있음을 시사합니다.
MedBright AI Investments Inc. (CSE:MBAI, OTCQB:MBAIF, FSE:Y30) a nommé Christopher Heath comme nouveau directeur général, avec effet au 9 août 2024. Heath apporte une expérience précieuse de son précédent rôle de PDG de Convalo Health Corp., un réseau de cliniques de traitement des drogues et de l’alcool. Son expertise dans les secteurs médical et technologique, combinée à plus d'une décennie d'expérience sur les marchés de capitaux publics, s'aligne sur la mission de MedBright d'investir dans des solutions de santé activées par l'IA.
L'entreprise a également annoncé la résiliation de la lettre d'intention précédemment annoncée concernant une acquisition proposée par Numinus Wellness Inc. Ce changement stratégique suggère que MedBright AI se concentre sur la croissance et le développement internes sous une nouvelle direction.
MedBright AI Investments Inc. (CSE:MBAI, OTCQB:MBAIF, FSE:Y30) hat Christopher Heath zum neuen Geschäftsführer ernannt, der am 9. August 2024 in Kraft tritt. Heath bringt wertvolle Erfahrungen aus seiner vorherigen Rolle als CEO von Convalo Health Corp., einem Netzwerk von Drogen- und Alkoholbehandlungskliniken, mit. Seine Expertise in den medizinischen und technologischen Sektoren, kombiniert mit über einem Jahrzehnt Erfahrung an den öffentlichen Kapitalmärkten, passt zur Mission von MedBright, in KI-gestützte Gesundheitslösungen zu investieren.
Das Unternehmen hat außerdem die Beendigung des zuvor angekündigten Absichtsschreibens bezüglich eines vorgeschlagenen Erwerbs durch Numinus Wellness Inc. bekannt gegeben. Dieser strategische Wandel deutet darauf hin, dass MedBright AI sich unter neuer Führung auf internes Wachstum und Entwicklung konzentriert.
- Appointment of experienced CEO Christopher Heath with relevant industry background
- New CEO's expertise aligns with company's mission in AI-enabled healthcare solutions
- Heath's experience in public capital markets could benefit shareholder value
- Termination of previously announced letter of intent for acquisition by Numinus Wellness Inc.
VANCOUVER, British Columbia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the "Company" or "MedBright AI") (CSE:MBAI, OTCQB:MBAIF, FSE:Y30) is pleased to announce that Christopher Heath has joined MedBright AI as Chief Executive Officer effective August 9, 2024.
Mr. Heath previously served as Chief Executive Officer at Convalo Health Corp., a publicly traded network of drug and alcohol inpatient and outpatient clinics that generated gross revenues of eight figures annually. Since Convalo, Mr. Heath has invested in and consulted for companies in the medical and technology spaces, helping to lead both startups and mature businesses forward in innovative ways. Mr. Heath has over a decade of experience in the public capital markets which has provided him with a comprehensive understanding of industry dynamics and financial strategies.
"Mr. Heath's combination of experience in leading a network of mental health clinics and his involvement in the medical and technology ecosystems aligns seamlessly with MedBright's mission of investing in companies that are using AI-enabled tools to improve patient outcomes while positively impacting medical practices' bottom lines," said Jaime Gerber, Chairman of MedBright AI. "Over the past decade, Mr. Heath has consistently demonstrated his ability to successfully lead and guide companies in a way that optimizes shareholder value."
Mr. Heath adds, "I’m excited to join the MedBright AI Investments leadership team at the start of what we believe will be an AI-led revolution in the healthcare sector. I look forward to leveraging my experience to drive innovation and growth in this burgeoning field."
The Company also announces that it has decided to terminate the letter of intent previously announced by the Company on June 20, 2024 regarding the proposed acquisition of the Company by Numinus Wellness Inc.
About MedBright AI Investments Inc.
MedBright AI is a capital allocator focused on investing in healthcare technology companies. The team at MedBright seeks to leverage the diverse background and skillsets of its management group and advisors, which include professionals from a variety of disciplines, including physicians and professors from Yale University Hospital, artificial intelligence specialists, and healthcare industry finance and management specialists, in order to identify and structure the Company’s investments.
For further information, please contact:
MedBright AI Investments Inc.
Mr. Chris Heath, Chief Executive Officer
Email: investors@medbright.ai
Phone: (604) 602-0001
www.medbright.ai
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: management’s beliefs regarding the alignment of Mr. Heath’s experience in leading a network of mental health clinics and his deep involvement in the MedTech ecosystem and the Company’s mission; and management’s beliefs regarding AI’s role in the healthcare sector, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" or occur.
Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: Mr. Heath’s experience will align with the Company’s mission; and the anticipated prominence of AI in the future healthcare sector. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: Mr. Heath’s experience will not align with the Company’s mission; and AI may not have as significant a role in the future healthcare sector as the Company anticipates.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
FAQ
Who is the new CEO of MedBright AI Investments (MBAIF) as of August 9, 2024?
What is Christopher Heath's background before joining MedBright AI Investments (MBAIF)?
What happened to MedBright AI Investments' (MBAIF) proposed acquisition by Numinus Wellness Inc.?
How does Christopher Heath's experience align with MedBright AI Investments' (MBAIF) goals?
